These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17188873)

  • 1. ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2.
    Kiselyov AS; Piatnitski EL; Samet AV; Kisliy VP; Semenov VV
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1369-75. PubMed ID: 17188873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template.
    Kiselyov AS; Semenova M; Semenov VV; Milligan D
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1913-9. PubMed ID: 16460936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3,4-Disubstituted isothiazoles: novel potent inhibitors of VEGF receptors 1 and 2.
    Kiselyov AS; Semenova M; Semenov VV
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1195-8. PubMed ID: 19124243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-(Azolylphenyl)-phthalazin-1-amines: Novel inhibitors of VEGF receptors I and II.
    Kiselyov AS; Semenov VV; Milligan D
    Chem Biol Drug Des; 2006 Dec; 68(6):308-13. PubMed ID: 17177892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability.
    Patel N; Sun L; Moshinsky D; Chen H; Leahy KM; Le P; Moss KG; Wang X; Rice A; Tam D; Laird AD; Yu X; Zhang Q; Tang C; McMahon G; Howlett A
    J Pharmacol Exp Ther; 2003 Sep; 306(3):838-45. PubMed ID: 12766257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.
    Kiselyov AS; Semenova M; Semenov VV; Piatnitski E
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1726-30. PubMed ID: 16364640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II.
    Kiselyov AS; Semenova M; Semenov VV; Piatnitski E; Ouyang S
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1440-4. PubMed ID: 16321531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel inhibitors of VEGF receptors-1 and -2 based on azole-5-carboxamide templates.
    Kiselyov AS; Milligan D; Ouyang X
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3550-7. PubMed ID: 17481893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1-(Azolyl)-4-(aryl)-phthalazines: novel potent inhibitors of VEGF receptors I and II.
    Kiselyov AS; Semenova M; Semenov VV; Piatnitski EL
    Chem Biol Drug Des; 2006 Nov; 68(5):250-5. PubMed ID: 17177884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II.
    Kiselyov AS; Piatnitski E; Semenova M; Semenov VV
    Bioorg Med Chem Lett; 2006 Feb; 16(3):602-6. PubMed ID: 16275072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (1,2,3-Triazol-4-yl)benzenamines: synthesis and activity against VEGF receptors 1 and 2.
    Kiselyov AS; Semenova M; Semenov VV
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1344-8. PubMed ID: 19188066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase.
    Piatnitski EL; Duncton MA; Kiselyov AS; Katoch-Rouse R; Sherman D; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4696-8. PubMed ID: 16143524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II.
    Duncton MA; Piatnitski EL; Katoch-Rouse R; Smith LM; Kiselyov AS; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1579-81. PubMed ID: 16386418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases.
    Nakamura H; Sasaki Y; Uno M; Yoshikawa T; Asano T; Ban HS; Fukazawa H; Shibuya M; Uehara Y
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5127-31. PubMed ID: 16893647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 1H-1,2,4-triazol-3-yl-anilines: novel potent inhibitors of vascular endothelial growth factor receptors 1 and 2.
    Kiselyov AS; Piatnitski E; Milligan D; Ouyang X
    Chem Biol Drug Des; 2007 May; 69(5):331-7. PubMed ID: 17539825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor in chronic rat allograft nephropathy.
    Malmström NK; Kallio EA; Rintala JM; Nykänen AI; Räisänen-Sokolowski AK; Paavonen T; Lemström KB; Koskinen PK
    Transpl Immunol; 2008 May; 19(2):136-44. PubMed ID: 18503889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
    Wissner A; Fraser HL; Ingalls CL; Dushin RG; Floyd MB; Cheung K; Nittoli T; Ravi MR; Tan X; Loganzo F
    Bioorg Med Chem; 2007 Jun; 15(11):3635-48. PubMed ID: 17416531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.
    Wissner A; Floyd MB; Johnson BD; Fraser H; Ingalls C; Nittoli T; Dushin RG; Discafani C; Nilakantan R; Marini J; Ravi M; Cheung K; Tan X; Musto S; Annable T; Siegel MM; Loganzo F
    J Med Chem; 2005 Dec; 48(24):7560-81. PubMed ID: 16302797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of quinoline amide derivatives as novel VEGFR-2 inhibitors.
    Yang Y; Shi L; Zhou Y; Li HQ; Zhu ZW; Zhu HL
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6653-6. PubMed ID: 20943391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.
    Borzilleri RM; Bhide RS; Barrish JC; D'Arienzo CJ; Derbin GM; Fargnoli J; Hunt JT; Jeyaseelan R; Kamath A; Kukral DW; Marathe P; Mortillo S; Qian L; Tokarski JS; Wautlet BS; Zheng X; Lombardo LJ
    J Med Chem; 2006 Jun; 49(13):3766-9. PubMed ID: 16789733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.